Aspire Biopharma Holdings (ASBP) Non-Current Assets (2022 - 2026)
Aspire Biopharma Holdings (ASBP) posted quarterly Non-Current Assets of $6.5 million for Q2 2024, down 67.41% year-over-year from $20.0 million in Q3 2023, and down 67.6% quarter-over-quarter from $20.1 million in Q1 2024.
Aspire Biopharma Holdings (ASBP) Non-Current Assets (2022 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Non-Current Assets for 3 consecutive years, with $6.5 million the latest figure, recorded in Q2 2024.
- In Q2 2024, Non-Current Assets fell 67.41% year-over-year to $6.5 million; the TTM figure through Jun 2025 stood at $6.5 million (down 90.14% YoY), while the FY2023 annual figure was $19.9 million, down 93.35% from the prior year.
- Non-Current Assets retreated to $6.5 million in Q2 2024 per ASBP's latest filing, from $20.1 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $302.2 million in Q1 2023 and bottomed at $6.5 million in Q2 2024.
- Historically, Non-Current Assets has averaged $157.5 million across 3 years, with a median of $157.7 million in 2022.
- On a YoY basis, Non-Current Assets climbed as much as 2.36% in 2023 and fell as far as 93.38% in 2023.
- Aspire Biopharma Holdings' Non-Current Assets stood at $299.1 million in 2022, then slumped by 93.35% to $19.9 million in 2023, then slumped by 67.21% to $6.5 million in 2024.
- Business Quant data shows ASBP's Non-Current Assets at $6.5 million in Q2 2024, $20.1 million in Q1 2024, and $19.9 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Aspire Biopharma Holdings | 8.30 Mn | -3.86 Mn | -30,086.00 | 75,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 75,000.00 |
| Jun 30, 2024 | 6.52 Mn |
| Mar 31, 2024 | 20.14 Mn |
| Dec 31, 2023 | 19.90 Mn |
| Sep 30, 2023 | 19.64 Mn |
| Jun 30, 2023 | 20.02 Mn |
| Mar 31, 2023 | 302.20 Mn |
| Dec 31, 2022 | 299.08 Mn |
| Sep 30, 2022 | 296.69 Mn |
| Jun 30, 2022 | 295.51 Mn |
| Mar 31, 2022 | 295.24 Mn |